首页> 外文OA文献 >Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

【2h】

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

机译：淋巴因子激活杀伤细胞的全身白细胞介素-2和肝脏活化杀伤细胞的养老液转移改善了用rituximab处理的复发B细胞淋巴瘤患者中的抗体依赖性细胞细胞毒性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jesús G. Berdeja; Allan Hess; David M. Lucas; Paul ODonnell; Richard F. Ambinder; Louis F. Diehl; Denise Carter-Brookins; Susan Newton; Ian W. Flinn;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity [J] . Garcia-Munoz Ricardo, Lopez-Diaz-de-Cerio Ascension, Feliu Jesus, Immunologic Research: A Selective Reference to Current Research and Practice . 2016,第2期

机译：滤泡性淋巴瘤：结合淋巴因子激活的杀手（LAK）细胞诱导的细胞毒性和利妥昔单抗和奥比妥珠单抗依赖性细胞毒性（ADCC）活性的体外作用
2. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab [J] . BittenbringJ.T., NeumannF., AltmannB., Journal of Clinical Oncology . 2014,第29期

机译：维生素D缺乏症会损害利妥昔单抗介导的细胞毒性，并影响接受或不接受利妥昔单抗治疗的弥漫性大B细胞淋巴瘤患者的结局
3. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. [J] . Wu L, Adams M, Carter T, Clinical cancer research: an official journal of the American Association for Cancer Research . 2008,第14期

机译：来那度胺增强利妥昔单抗治疗的CD20 +肿瘤细胞的自然杀伤细胞和单核细胞介导的抗体依赖性细胞毒性。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL [O] . Yaya Chu, Aradhana Awasthi, Sanghoon Lee, 2020

机译：ObInutuzumab（Ga101）与Rituximab显着增强了细胞死亡抗体依赖性细胞毒性并改善了异种移植Nod-Scid IL2RGNULL（NSG）小鼠模型中的CD20 +原发性纵隔B细胞淋巴瘤（PMBL）的整体存活率：潜在的靶向剂治疗PMBL.
6. Interleukin-2 and Lymphokine-Activated Killer Cell Therapy in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab [O] . Vincenzo Pitini, Carmela Arrigo, Claudia Naro, 2007

机译：白细胞介素-2和淋巴因子活化杀伤细胞疗法，患者用rituximab处理的B细胞淋巴瘤

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

著录项

引文网络

相似文献

相关主题

期刊订阅